Implementation of the Anchor-Based Indirect Comparison Method for Equivalence Margin Derivation in Biosimilar Development
<b>Background/Objectives</b>: To derive the equivalence margin (EQM), typically, a “classical” meta-analysis on direct within-trial estimation of the effect size of the reference drug compared to the placebo or standard of care is performed: a certain factor of the 95% confidence interva...
Saved in:
| Main Authors: | Claudia Hemmelmann, Rachid El Galta, Jessie Wang, Susanne Schmitt, Ramin Arani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/3/285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01) -
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01) -
Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept)
by: Valentin Kopanarov, et al.
Published: (2025-07-01) -
BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01) -
Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections
by: Mohamed Halawa, et al.
Published: (2025-04-01)